Zyprexa (Olanzapine): Clinical Indications, Dosing, and Monitoring
Zyprexa (olanzapine) is FDA-approved for schizophrenia, bipolar I disorder (manic/mixed episodes), and agitation in schizophrenia/bipolar mania, with off-label but guideline-supported use in chemotherapy-induced nausea/vomiting (CINV) and delirium management in cancer patients. 1
FDA-Approved Indications
Schizophrenia (Adults)
- Starting dose: 5-10 mg once daily
- Target dose: 10 mg/day
- Dose range: 5-20 mg/day
- Titration: Adjust by 5 mg increments at intervals ≥1 week 1
Bipolar I Disorder (Manic/Mixed Episodes)
- Monotherapy starting dose: 10-15 mg once daily
- Combination therapy (with lithium/valproate): Start 10 mg once daily
- Dose range: 5-20 mg/day 1
Acute Agitation (IM formulation)
- Dose: 10 mg IM (lower doses of 5-7.5 mg may be appropriate)
- Repeat dosing: 5-10 mg IM 2 hours after initial dose if needed
- Maximum: 30 mg/day; no more than 3 injections in 24 hours 1
Elderly Patient Dosing
In elderly patients, start at 2.5-5 mg/day and titrate cautiously due to increased mortality risk in dementia-related psychosis (FDA black box warning). 2
Specific Elderly Dosing by Indication:
Delirium in cancer patients:
- Start 2.5-5 mg PO/SC stat
- If scheduled dosing needed: 2.5-5 mg daily (usually at bedtime)
- Reduce dose in hepatic impairment 3
Alzheimer's disease with psychosis/agitation:
- Start 2.5 mg at bedtime
- Maximum: 10 mg/day in divided doses
- Note: 5-10 mg/day doses showed efficacy in nursing home residents, but carries dementia-related mortality risk 4, 5
CINV in elderly/oversedated patients:
- Consider 5 mg dose (rather than standard 10 mg) 2
Off-Label Guideline-Supported Uses
Chemotherapy-Induced Nausea/Vomiting (Category 1 Recommendation)
For highly emetogenic chemotherapy (HEC), olanzapine 10 mg PO once daily (given before chemotherapy, then daily for 3 days) combined with NK1 antagonist, 5-HT3 antagonist, and dexamethasone is first-line therapy. 2
This 4-drug regimen demonstrated:
- Complete response rates: 86% vs 65% (acute), 67% vs 52% (delayed), 64% vs 41% (overall) compared to placebo
- Superior nausea control: 74% vs 45% (acute), 42% vs 25% (delayed) 2
Breakthrough emesis: Olanzapine is Category 1 for rescue therapy 2
Delirium Management (Cancer Patients)
For delirium with perceptual disturbances or severe agitation, start olanzapine 2.5-5 mg PO/SC as needed, with scheduled dosing (2.5-5 mg daily at bedtime) if symptoms persist. 3
- Use lowest effective dose for shortest duration
- Reduce dose in elderly and hepatically impaired patients
- Available as orally disintegrating tablet (ODT) and IM formulation 3
Critical Safety Warnings
Black Box Warning
Increased mortality in elderly patients with dementia-related psychosis - olanzapine is not approved for this indication 2, 1
Major Precautions
Metabolic effects (especially in adolescents and young adults):
- Weight gain (most prominent adverse effect)
- Hyperglycemia/diabetes mellitus
- Dyslipidemia
- Monitor baseline and periodically: weight, BMI, fasting glucose, lipid panel 1
Cardiovascular:
- Orthostatic hypotension (especially with IM use)
- QTc prolongation risk - avoid in patients with existing QTc prolongation or congestive heart failure 4
Neurological:
- Extrapyramidal symptoms (lower risk than typical antipsychotics)
- Tardive dyskinesia risk with prolonged use
- Neuroleptic malignant syndrome (rare but serious) 1
Sedation:
- Fatigue, drowsiness, sleep disturbances common 2
- Caution: Fatalities reported with concurrent high-dose olanzapine and benzodiazepines 3
Other:
- Constipation (more common at doses ≥40 mg/day) 6
- DRESS syndrome (rare but serious skin reaction) 2
- Hyperprolactinemia 1
Drug Interactions
Avoid excessive dopamine blockade: Use caution when combining with metoclopramide, phenothiazines, or haloperidol 2
Contraindicated/high-risk combinations:
- Clozapine + carbamazepine
- High-dose olanzapine + benzodiazepines (respiratory depression/oversedation risk) 3, 7
Requires extra monitoring:
- Lithium, carbamazepine, lamotrigine, valproate
- Strong CYP450 inhibitors (fluoxetine, fluvoxamine, paroxetine) - may increase olanzapine levels 7
Therapeutic Drug Monitoring
Therapeutic reference range: 20-40 ng/mL (trough level, 12 hours post-dose) 8
- Levels ≥20-23 ng/mL associated with therapeutic response in schizophrenia 9, 8
- Optimal D2-receptor occupancy (65-80%) occurs at 17-44 ng/mL 8
- Males require higher doses than females to achieve therapeutic levels 9
- Consider TDM in treatment-resistant cases or suspected non-adherence 10, 8
Duration of Treatment
Recommended treatment duration before attempting taper:
- Delirium: 1 week 3
- Agitated dementia: Taper within 3-6 months to determine lowest effective maintenance dose 4
- Schizophrenia: Indefinite at lowest effective dose 7
- Delusional disorder: 6 months to indefinite 7
- Psychotic depression: 6 months 7
- Mania with psychosis: 3 months 7
Special Populations to Avoid
Avoid or use extreme caution in:
- Dementia-related psychosis (black box warning) 1
- Parkinson's disease or Lewy body dementia (use quetiapine instead) 3
- Diabetes, dyslipidemia, obesity (prefer risperidone or quetiapine) 7
- QTc prolongation or congestive heart failure 7
Formulations
- Tablets: 2.5,7.5,10,15,20 mg
- Orally disintegrating tablets (ZYDIS): 5,10,15,20 mg
- IM injection: 10 mg/vial (for acute agitation)
- Long-acting injectable (LAI): Not approved for patients <18 years 1, 11
Key Clinical Pearls
- High-dose olanzapine (≥40 mg/day) is associated with longer hospital stays and increased constipation without clear efficacy advantage over standard dosing 6
- In adolescents, metabolic adverse effects are more pronounced than in adults; position as second-line agent with stringent metabolic monitoring 11
- For CINV, olanzapine-containing regimens are not FDA-approved but have strong guideline support (NCCN Category 1) 2, 12
- Thoughtful patient selection is critical - balance efficacy against metabolic and cardiovascular risks 2